| Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations S Haraldsdottir, H Hampel, J Tomsic, WL Frankel, R Pearlman, ... Gastroenterology 147 (6), 1308-1316. e1, 2014 | 406 | 2014 |
| NCCN guidelines insights: genetic/familial high-risk assessment: colorectal, version 2.2019: featured updates to the NCCN guidelines S Gupta, D Provenzale, X Llor, AL Halverson, W Grady, DC Chung, ... Journal of the National Comprehensive Cancer Network 17 (9), 1032-1041, 2019 | 251 | 2019 |
| Colorectal cancer-review S Haraldsdottir, HM Einarsdottir, A Smaradottir, A Gunnlaugsson, ... Laeknabladid 100 (2), 75-82, 2014 | 197 | 2014 |
| Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2 S Haraldsdottir, T Rafnar, WL Frankel, S Einarsdottir, A Sigurdsson, ... Nature communications 8 (1), 14755, 2017 | 137 | 2017 |
| Prostate cancer incidence in males with Lynch syndrome S Haraldsdottir, H Hampel, L Wei, C Wu, W Frankel, T Bekaii-Saab, ... Genetics in medicine 16 (7), 553-557, 2014 | 137 | 2014 |
| Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro S Haraldsdóttir, E Guðlaugsdóttir, K Ingólfsdóttir, HM Ögmundsdóttir Planta medica 70 (11), 1098-1100, 2004 | 87 | 2004 |
| Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome R Pearlman, S Haraldsdottir, A De La Chapelle, JG Jonasson, ... Journal of medical genetics 56 (7), 462-470, 2019 | 71 | 2019 |
| Management of borderline resectable pancreatic cancer DAS Toesca, AJ Koong, GA Poultsides, BC Visser, S Haraldsdottir, ... International Journal of Radiation Oncology* Biology* Physics 100 (5), 1155-1174, 2018 | 58 | 2018 |
| Promising new agents for colorectal cancer S Das, KK Ciombor, S Haraldsdottir, RM Goldberg Current treatment options in oncology 19, 1-14, 2018 | 55 | 2018 |
| Effects of tenuiorin and methyl orsellinate from the lichen Peltigera leucophlebia on 5-/15-lipoxygenases and proliferation of malignant cell lines in vitro K Ingólfsdóttir, GF Gudmundsdóttir, HM Ögmundsdóttir, K Paulus, ... Phytomedicine 9 (7), 654-658, 2002 | 55 | 2002 |
| Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses S Haraldsdottir, H Hampel, C Wu, DY Weng, PG Shields, WL Frankel, ... Genetics in medicine 18 (9), 863-868, 2016 | 49 | 2016 |
| Diagnostic accuracy of 64-slice multidetector CT for detection of in-stent restenosis in an unselected, consecutive patient population S Haraldsdottir, T Gudnason, AF Sigurdsson, J Gudjonsdottir, SJ Lehman, ... European journal of radiology 76 (2), 188-194, 2010 | 46 | 2010 |
| Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis S Haraldsdottir, R Roth, R Pearlman, H Hampel, CA Arnold, WL Frankel Familial Cancer 15, 253-260, 2016 | 45 | 2016 |
| Frequent PIK3CA mutations in colorectal and endometrial tumors with 2 or more somatic mutations in mismatch repair genes SA Cohen, EH Turner, MB Beightol, A Jacobson, TA Gooley, SJ Salipante, ... Gastroenterology 151 (3), 440-447. e1, 2016 | 44 | 2016 |
| Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. N Bahary, A Wang-Gillam, S Haraldsdottir, BG Somer, JS Lee, ... Journal of Clinical Oncology 36 (15_suppl), 4015-4015, 2018 | 42 | 2018 |
| Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome JA Hemminger, R Pearlman, S Haraldsdottir, D Knight, JG Jonasson, ... Human pathology 78, 125-130, 2018 | 40 | 2018 |
| An update on clinical trials of targeted therapies in thyroid cancer S Haraldsdottir, MH Shah Oncology in Clinical Practice 10 (2), 121-130, 2014 | 40 | 2014 |
| Immune‐related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with Food and Drug Administration‐approved indications for … S Das, KK Ciombor, S Haraldsdottir, Y Pumpalova, IH Sahin, G Pineda, ... The oncologist 25 (8), 669-679, 2020 | 39 | 2020 |
| Microsatellite instability and adjuvant chemotherapy in stage II colon cancer JL Koenig, DAS Toesca, JP Harris, CJ Tsai, S Haraldsdottir, AY Lin, ... American Journal of Clinical Oncology 42 (7), 573-580, 2019 | 36 | 2019 |
| Implementing systematic genetic counseling and multigene germline testing for individuals with pancreatic cancer A Chittenden, S Haraldsdottir, C Ukaegbu, M Underhill-Blazey, S Gaonkar, ... JCO oncology practice 17 (2), e236-e247, 2021 | 35 | 2021 |
